NCT03939845 is a Phase 3 clinical trial of RT in Carcinoma, Hepatocellular, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT03939845?

NCT03939845 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT03939845?

Interventions in NCT03939845: RT, TACE.

What condition does NCT03939845 study?

NCT03939845 studies Carcinoma, Hepatocellular.

Is NCT03939845 still recruiting?

NCT03939845 is currently status unknown. Last updated 7 May 2019.

Last reviewed 2019-05-07 · How we verify

NCT03939845

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi

Status unknown Phase 3 Last updated 7 May 2019

What this trial tests

Phase 3 trial testing RT in Carcinoma, Hepatocellular in 180 participants. Status unknown.

Timeline

23 April 2019

Primary endpoint
23 April 2021

23 April 2022

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	180
Start date	23 April 2019
Primary completion	23 April 2021
Estimated completion	23 April 2022
Sites	1 location across China

Drugs / interventions tested

RT
TACE

Conditions studied

Carcinoma, Hepatocellular — all drugs for Carcinoma, Hepatocellular →

Sponsor

Shanghai Zhongshan Hospital

Who can join

18 and older, any sex, with Carcinoma, Hepatocellular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The 1-year and 2-year overall survival rate (OS), local control rate (FFLP), disease-free progression time (PFS), and side effects were compared in patients with hepatocellular carcinoma limited to intrahepatic unresectable hepatocellular carcinoma with portal venous thrombosis combined with or without external radiotherapy, providing a basis for the development of relevant guidelines.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations.
Hatzidakis A, Müller L, Krokidis M, Kloeckner R. · · 2022 · cited 17× · PMID 35626073 · DOI 10.3390/cancers14102469
Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure.
Farsad K, Nabavizadeh N, Kardosh A, Jou JH, et al · · 2020 · cited 9× · PMID 33490212 · DOI 10.21037/atm-20-4164

Verify or expand the search:

Other trials of RT

Trials testing the same drug.

NCT06214572 — Radiation Therapy in Unresectable Gall Bladder Cancer · Phase 2, PHASE3 · recruiting
NCT06356935 — Effects of Heavy-load Resistance Training · NA · completed
NCT05761054 — Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT) · NA · recruiting
NCT05068453 — Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis · Phase 1 · unknown
NCT04558879 — Exercise and Sleep in Parkinson's Disease · NA · unknown

Other recruiting trials for Carcinoma, Hepatocellular

Currently open trials in the same condition.

NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT06742892 — A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to · Phase 2 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06349980 — A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W · Phase 2 · recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03939845 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 7 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03939845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing